Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix May Get Its Own Stock From Parent Acacia

NEW YORK, March 21 - CombiMatrix may have its own stock if a plan floated by its parent company, Acacia Research, is approved.

 

Acacia's board of directors on Thursday gave the green light to the company's plan to divide its common stock into two new classes: the new CombiMatrix stock and Acacia Technologies stock, which would reflect Acacia's media technology business.

 

If shareholders of Newport Beach, Calif.-based Acacia approve the plan in their meeting on May 14, holders of Acacia Research stock would receive shares of both new classes in exchange for the shares they now hold. The new shares would be traded separately on the Nasdaq stock exchange.

Acacia's and CombiMatrix's board have also approved plans for Acacia to buy the minority stockholder interest in CombiMatrix. The proposed acquisition would have through a merger in which minority stockholders of CombiMatrix would receive shares of the new CombiMatrix stock in exchange for their existing shares. Stockholders of both companies must also approve this proposition.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.